- Home
- MGNI vs LIVN Comparison
MGNI vs LIVN Comparison
Compare MGNI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- LIVN
- Stock Information
- Founded
- MGNI 2007
- LIVN 1987
- Country
- MGNI United States
- LIVN United Kingdom
- Employees
- MGNI N/A
- LIVN N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MGNI Technology
- LIVN Health Care
- Exchange
- MGNI Nasdaq
- LIVN Nasdaq
- Market Cap
- MGNI 2.4B
- LIVN 2.1B
- IPO Year
- MGNI N/A
- LIVN 1993
- Fundamental
- Price
- MGNI $18.72
- LIVN $45.51
- Analyst Decision
- MGNI Strong Buy
- LIVN Strong Buy
- Analyst Count
- MGNI 13
- LIVN 7
- Target Price
- MGNI $19.23
- LIVN $59.29
- AVG Volume (30 Days)
- MGNI 1.9M
- LIVN 601.6K
- Earning Date
- MGNI 08-06-2025
- LIVN 07-30-2025
- Dividend Yield
- MGNI N/A
- LIVN N/A
- EPS Growth
- MGNI N/A
- LIVN N/A
- EPS
- MGNI 0.21
- LIVN N/A
- Revenue
- MGNI $674,622,000.00
- LIVN $1,275,380,000.00
- Revenue This Year
- MGNI $0.32
- LIVN $8.10
- Revenue Next Year
- MGNI $11.02
- LIVN $5.76
- P/E Ratio
- MGNI $87.36
- LIVN N/A
- Revenue Growth
- MGNI 5.59
- LIVN 7.62
- 52 Week Low
- MGNI $8.22
- LIVN $32.48
- 52 Week High
- MGNI $21.29
- LIVN $57.35
- Technical
- Relative Strength Index (RSI)
- MGNI 69.84
- LIVN 56.88
- Support Level
- MGNI $16.99
- LIVN $44.01
- Resistance Level
- MGNI $18.63
- LIVN $47.88
- Average True Range (ATR)
- MGNI 0.62
- LIVN 1.04
- MACD
- MGNI 0.03
- LIVN -0.23
- Stochastic Oscillator
- MGNI 80.91
- LIVN 53.44
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.